© 2022 MJH Life Sciences and Dermatology Times and Multimedia Medical, LLC. All rights reserved.
© 2022 MJH Life Sciences™ , Dermatology Times and Multimedia Medical, LLC. All rights reserved.
Linda Stein Gold, MD, and Matthew Zirwas, MD, provide a discussion on the role of JAK inhibitors in inflammatory diseases.
December 22nd 2021
Linda Stein Gold, MD, provides an overview of the four JAK inhibitors currently available for treating inflammatory diseases.
January 3rd 2022
Key opinion leaders explain the box warnings and safety profiles of JAK inhibitors.
January 5th 2022
Matthew Zirwas, MD, breaks down the safety of JAK inhibitors based on clinical trial data.
January 17th 2022
Clinicians provide insight into the risk of high systemic absorption levels with JAK inhibitor treatments.
January 19th 2022
Dr Matthew Zirwas describes his experience using JAK inhibitor ruxolitinib in his clinical practice.
January 26th 2022
Linda Stein Gold, MD, and Matthew Zirwas, MD, share some advice for clinicians on how to discuss JAK inhibitors with patients.
February 2nd 2022
Experts outline strategies for patient conversations around the black box warning.